People with metastatic breast cancer, brain metastases, and type 2 diabetes who used GLP-1 agonists had a 32% lower risk of death over 3 years compared to non-users, according to new research. The results are promising since people with brain mets often have worse survival outcomes. As more people take GLP-1s like Ozempic (chemical name: semaglutide), scientists have studied if the drugs may do more than just help people lose weight or manage type 2 diabetes.